ACE OncoCast

Updates on Oncogene-Driven NSCLC from Vienna: Targeting KRAS G12C mutation

ACE Oncology Season 4 Episode 2

In this episode, our experts discuss current and new strategies for targeting KRAS G12C mutation. Hear about emerging strategies to enhance activity of current treatment options in this molecular subtype.